Anti-PD1, which is one of the more potent checkpoint blockade treatments with very mild side effects, has just been approved for lung cancer.
There have been remarkable results of anti-PD1 causing remissions in heavily pretreated Hodgkin's Lymphoma patients.
Here we examine why this cancer immunotherapy can change the way Hodgkin's Lymphoma patients are treated in the future.
Hodgkin's Lymphoma is a good target for anti-PD1.
The results are coming out at the American Society of Hematology (ASH) conference, December 2014 and creating great excitement.
This is an excellent video explaining immunotherapy in lung cancer, primarily focusing on anti-PD1.
This video was published November 4, 2014 by Global Resource for Advancing Cancer Education (GRACE).
Dr. Jack West (Swedish Cancer Center, Seattle) moderates this discussion with Dr. Julie Brahmer (John Hopkins, Baltimore) and Dr. Ben Creelan (Moffitt Cancer Center, Tampa).
How to proceed after a cancer diagnosis
MRI and CT Scan Tips
Tips for Visiting Cancer Patients
10+ Gift Ideas for Cancer Patients
Anti-PD1, which is one of the more potent checkpoint blockade treatments with very mild side effects, has just been approved for lung cancer.
There have been remarkable results of anti-PD1 causing remissions in heavily pretreated Hodgkin's Lymphoma patients.
Anti-PD1 treatments are showing tremendous results for Hodgkin's Lymphoma patients who have not responded to conventional treatments.
